E191 - Psoriasis an update on topical and systemic therapies

Jo Cheah chats to dermatologist Jonathan Chan about the latest therapies for psoriasis. Jonathan outlines the different treatments for mild to moderate and moderate to severe psoriasis, and when to refer patients to a non-GP specialist. They discuss the benefits and risks associated with biologic medicines for psoriasis, and considerations for patients with comorbidities. Read the full article by Jonathan in Australian Prescriber.

Dhineli Perera talks to pharmacists Amy Legg and Tony Lai about their paper on the safe and effective use of vancomycin. They discuss the evolution of vancomycin therapeutic drug monitoring, including trough concentrations, and demystify AUC monitoring. They cover current recommendations, including targets for drug efficacy and safety, and priority patient groups. Read the full article by Amy, Tony, and their co-authors, in Australian Prescriber.

Justin Coleman speaks with Alice Poulton, genetic counsellor, about noninvasive prenatal testing (NIPT) to screen for aneuploidies such as trisomy 21 (Down syndrome). Alice explains how NIPT differs from serum screening and ultrasound options, and when each option may be used. The conversation also covers advice on interpreting the NIPT results and when invasive testing may be offered. Read the full paper in Australian Prescriber.

David Liew talks to Linny Phuong, paediatric infectious diseases physician, about changes to prevention and management of respiratory syncytial virus (RSV). They discuss how RSV infections affect communities in Australia, high-risk groups to watch out for, and when to test for RSV. Linny also outlines available RSV immunisations for different populations. Read the full article by Linny and her co-author, David Foley, in Australian Prescriber.

Dhineli Perera chats with Allen Cheng, director of Infectious Diseases at Monash Health and member of the Antibiotic Expert Group, about some of the updates in the latest version of Therapeutic Guidelines: Antibiotic. Allen talks about changes to severity assessment and treatment for community-acquired pneumonia, updated antimicrobial dosing advice, a new tiered approach for managing patients with sepsis and much more.

Jo Cheah talks to Bronwyn Jenkins, consultant neurologist, about the role of calcitonin gene-related peptide (CGRP)–targeted therapies in migraine treatment. Bronwyn explains the difference between tension-type headaches and migraines, and outlines current treatment options. The conversation also covers adverse effects, patient eligibility, and other important considerations for prescribers. Read the full article in Australian Prescriber.

Justin Coleman speaks with Kate Ziser, a pharmacist at the Princess Alexandra Hospital in Brisbane, about her paper on the role of triple antithrombotic therapy in patients with atrial fibrillation following coronary stent insertion. Kate explains when triple therapy is indicated, the duration of therapy, and the step-down approach to antithrombotic therapy. Read the full article by Kate and her co-authors in Australian Prescriber.

Laura Beaton chats with Nadia Mouchaileh, senior pharmacist, and Jillian Cameron, head of movement disorders and consultant neurologist at Austin Health, about device-assisted therapies for Parkinson disease. They discuss the benefits vs traditional therapies, when to refer patients to a specialised movement disorder centre and what to look for when caring for a patient using a device. Read the full article in Australian Prescriber.

Jo Cheah talks to Debra Kennedy, director of MotherSafe, about her paper on drug safety in pregnancy. Debra discusses the key considerations when stopping or starting a medicine during pregnancy, and the ways in which medicines can affect developing fetuses. Debra also explains the Australian categorisation system for prescribing medicines in pregnancy. Read the full article by Debra and her co-author, Ronald Batagol, in Australian Prescriber.

Dhineli Perera speaks with Lee Fong, a medical advisor for the Australian Commission on Safety and Quality in Health Care, about the need to establish a national clinical care standard for people with chronic obstructive pulmonary disease (COPD). Lee explains how the Standard can be used to identify gaps in care and optimise the management of patients with COPD. Read the full article by Lee and his co-authors in Australian Prescriber.